Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Rhea-AI Summary

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit.

The company's Founder, President, and CEO, Dr. Laxminarayan Bhat, will deliver a webcasted presentation on Monday, January 13, 2025, at 12:30 p.m. ET. The virtual event will be accessible through the conference homepage at lythampartners.com/health2025/ or directly via the company-specific link.

Investors will have the opportunity to schedule one-on-one meetings following the event by contacting Lytham Partners representatives. A replay of the presentation will be made available through the same web links.

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

Company Webcast

The webcasted presentation will take place at 12:30 p.m. ET on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/rvph. A replay of the presentation will also be available through same links.

1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at RVPH@LythamPartners.com.

About Reviva 

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. 

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva's (RVPH) presentation at the Lytham Partners Healthcare Summit 2025?

Reviva's presentation is scheduled for Monday, January 13, 2025, at 12:30 p.m. ET during the virtual Lytham Partners 2025 Investor Healthcare Summit.

How can investors access RVPH's presentation at the Lytham Partners Summit?

Investors can access the presentation through the conference homepage at lythampartners.com/health2025/ or directly through the company-specific link at lythampartners.com/health2025/rvph.

What therapeutic areas does Reviva (RVPH) focus on?

Reviva focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

How can investors arrange 1x1 meetings with Reviva (RVPH) management?

Investors can arrange one-on-one meetings by contacting their Lytham representative at RVPH@LythamPartners.com after the event.